Acurx partners with Leiden UMC to develop first 3D structure of MRSA PolC bound to its antibiotic inhibitor

• Acurx formed a research partnership with Leiden University Medical Center to advance DNA polymerase IIIC (PolC) inhibitor antibiotics.
• Work targets the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor to support new antibiotic discovery.
• Partnership builds on 2025 structural results for Enterococcus PolC complexes that clarified ibezapolstat’s mechanism and resistance profile.
• Program aims to accelerate systemic Gram-positive agents with “gut-sparing” potential, supported by initial MRSA mouse data cited from University of Houston studies.
• Ibezapolstat for C. difficile is Phase 3-ready, with FDA signaling an NDA path based on a single Phase 3 trial plus supporting Phase 2 data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608100801PR_NEWS_USPR_____NY21862) on August 10, 2026, and is solely responsible for the information contained therein.